8-K: Veru Reports Q1 FY26 Results, Advances Obesity Drug Enobosarm

Veru Inc. announced its fiscal 2026 first quarter financial results and provided updates on its enobosarm clinical program for obesity, including plans to initiate the Phase 2b PLATEAU trial.

Summary

• Veru Inc. reported financial results for its fiscal 2026 first quarter ended December 31, 2025.
• The Phase 2b PLATEAU clinical trial, evaluating enobosarm in combination with semaglutide for older patients with obesity, is on track to initiate in Q1 calendar 2026.
• Interim analysis results for the PLATEAU trial are anticipated in Q1 calendar year 2027.
• Positive results from the Phase 2b QUALITY clinical trial confirmed enobosarm plus semaglutide led to greater fat loss while preserving lean mass and physical function in older patients with obesity.
• The FDA provided regulatory clarity for enobosarm, outlining two possible pathways for approval based on incremental weight loss or clinically significant positive benefits such as physical function preservation.
• The FDA confirmed enobosarm 3 mg as an acceptable dosage for future clinical development.
• The FDA's announcement on December 19, 2025, that total hip bone mineral density (BMD) is a validated surrogate endpoint for osteoporosis drug development, potentially offers another primary endpoint for enobosarm, especially given reported GLP-1 RA therapy reductions in hip BMD and increased fracture risk.
• Cash, cash equivalents, and restricted cash increased to $33.0 million as of December 31, 2025, from $15.8 million as of September 30, 2025.
• Net loss decreased to $5.3 million, or $0.26 per share, for Q1 FY2026, compared to $8.9 million, or $0.61 per share, for Q1 FY2025.
• Operating loss from continuing operations decreased to $5.4 million for Q1 FY2026 from $10.2 million for Q1 FY2025.
• Research and development expenses decreased to $1.3 million for Q1 FY2026 from $5.7 million for Q1 FY2025.
• General and administrative expenses decreased to $4.1 million for Q1 FY2026 from $5.2 million for Q1 FY2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, driven by improved financial metrics, significant cash increase, and clear progress in the enobosarm clinical program with favorable FDA feedback, despite ongoing losses.

Positives

• Cash, cash equivalents, and restricted cash significantly increased to $33.0 million as of December 31, 2025, from $15.8 million as of September 30, 2025.
• Net loss decreased to $5.3 million ($0.26 per share) in Q1 FY2026 from $8.9 million ($0.61 per share) in Q1 FY2025.
• Operating loss from continuing operations decreased to $5.4 million in Q1 FY2026 from $10.2 million in Q1 FY2025.
• Research and development expenses decreased to $1.3 million in Q1 FY2026 from $5.7 million in Q1 FY2025.
• General and administrative expenses decreased to $4.1 million in Q1 FY2026 from $5.2 million in Q1 FY2025.
• Positive Phase 2b QUALITY clinical trial results demonstrated enobosarm plus semaglutide led to greater fat loss and preserved lean mass and physical function.
• Successful FDA meeting provided regulatory clarity for enobosarm, outlining two acceptable pathways for approval based on incremental weight loss or clinically significant benefits.
• The FDA confirmed enobosarm 3 mg as an acceptable dosage for future clinical development.
• The FDA's announcement of total hip BMD as a validated surrogate endpoint for osteoporosis offers a potential new primary endpoint for enobosarm, especially given GLP-1 RA's reported reduction in hip BMD and increased fracture risk.
• The Phase 2b PLATEAU clinical trial is on track to initiate in Q1 calendar 2026.

Negatives

• The company continues to report a net loss of $5.3 million and an operating loss of $5.4 million for the quarter.

Risks

• Clinical study results may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development.
• The FDA may ultimately disagree that the company's clinical trials support approval, despite prior feedback.
• Inability to reach agreement with the FDA on study design requirements for planned clinical studies, including for the Phase 2b program for enobosarm as a weight loss or body composition drug and the number of future Phase 3 studies to be required and their cost.
• Potential delays in the timing of and results from clinical trials and studies, including as a result of an inability to enroll sufficient numbers of subjects or enroll subjects in accordance with planned schedules.
• The ability to fund planned clinical development as well as other operations of the company.
• Whether the company will be able to partner with another company in the development of enobosarm.
• The timing of any submission to the FDA or any other regulatory authority and any determinations made by them.
• The potential for disruptions at the FDA or other government agencies to negatively affect the business, including as a result of a future shutdown of the U.S. government.
• Any products of the company, if approved, possibly not being commercially successful.
• The ability of the company to obtain sufficient financing, including any partnership or collaboration agreements, on acceptable terms when needed to fund development and operations and to enable the company to continue as a going concern.
• Demand for, market acceptance of, and competition against any of the company's products or product candidates.
• New or existing competitors with greater resources and capabilities and new competitive product approvals and/or introductions.
• Changes in regulatory practices or policies or government-driven healthcare reform efforts, including pricing pressures and insurance coverage and reimbursement changes.
• The company's ability to protect and enforce its intellectual property.
• Costs and other effects of litigation, including regulatory challenges, product liability claims, intellectual property, securities litigation and litigation with the purchaser of the company's FC2 business.
• The company's ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives.
• The company's ability to successfully integrate acquired businesses, technologies or products.

Future Outlook

The company anticipates initiating the Phase 2b PLATEAU clinical trial in Q1 calendar 2026, with interim analysis results expected in Q1 calendar 2027. They expect enobosarm, in combination with GLP-1 RAs, to lead to clinically meaningful incremental weight reduction and preserve muscle mass and physical function in longer studies. The FDA has provided two potential regulatory pathways for approval, based on incremental weight loss or clinically significant positive benefits like physical function preservation or improving bone mineral density.

Management Comments

• "The strategy for the next generation of obesity drugs should be a combination therapy with GLP-1 receptor agonists for patients to ONLY lose fat, while preserving lean mass and physical function and increasing bone mineral density for the highest quality weight reduction." Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.
• "Veru's completed positive Phase 2b QUALITY clinical trial provided the proof of concept that enobosarm could be that next generation drug in combination with a GLP-1 RA to make the weight loss journey more selective for only fat while preserving lean mass and physical function in older patients who have obesity lessening the potential risk of loss of balance, and fractures." Mitchell Steiner, M.D.
• "An emerging, common, and serious clinical and therapeutic challenge with GLP-1 RA monotherapy is that 88% of patients with obesity after one year on drug hit a weight loss plateau where they stop losing additional weight while on a GLP-1 RA based on the SURMOUNT-1 study conducted by Eli Lilly and Company." Mitchell Steiner, M.D.
• "Enobosarm has been shown to directly burn fat and to preserve muscle to increase physical function and burn more calories which could help to break through the weight loss plateau leading to incremental weight reduction." Mitchell Steiner, M.D.
• "After serving as the Principal Investigator of the positive data Phase 2 QUALITY clinical trial, I am pleased to serve as the Principal Investigator for this important Phase 2b PLATEAU enobosarm clinical trial." Steven Heymsfield, MD, Principal Investigator.
• "Older patients with obesity receiving a GLP-1 RA are at risk for loss of muscle and physical function and could benefit from enobosarm to preserve muscle mass and physical function to improve the quality of weight loss." Steven Heymsfield, MD.

Industry Context

StockSavvy.ai notes that Veru is strategically positioning enobosarm to address significant limitations of current GLP-1 receptor agonist (GLP-1 RA) monotherapies for obesity, specifically the loss of lean muscle mass, decline in physical function, and the common weight loss plateau observed in a high percentage of patients (88% in SURMOUNT-1). This approach aims to differentiate enobosarm by focusing on "quality weight reduction" through fat-selective loss and muscle preservation, a critical unmet need, especially in older patients.

Comparison to Industry Standards

• The filing highlights that 88% of patients on GLP-1 RA monotherapy, based on Eli Lilly and Company's SURMOUNT-1 study, hit a weight loss plateau after one year, with 62.6% still clinically obese. Veru's enobosarm aims to break through this plateau.
• Novo Nordisk A/S's Wegovy (semaglutide) FDA label was updated to include increased risk of hip and pelvic fractures based on the SELECT cardiovascular trial, where 4-5 times more fractures were reported on semaglutide than placebo in female patients and those 75 and older. Enobosarm's potential to increase bone mineral density could offer a significant advantage over existing GLP-1 RAs.
• Veru's Phase 2b QUALITY clinical trial results, showing greater fat loss and lean mass preservation with enobosarm plus semaglutide, contrast with the general muscle loss observed with GLP-1 RA monotherapies.
• The selection of semaglutide for the PLATEAU study leverages previous experience and the availability of an oral formulation, potentially offering a competitive edge over tirzepatide (e.g., Mounjaro, Zepbound) which currently lacks an oral formulation for combination therapy.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical trial progress, clear regulatory pathways, and improved financial liquidity. Reduced net and operating losses may instill more confidence.
• Patients with Obesity: Potential for a new, more effective combination therapy (enobosarm + GLP-1 RA) that addresses limitations of current treatments, such as muscle loss and weight loss plateaus, leading to higher quality weight reduction and improved physical function and bone health.
• Healthcare Providers: New treatment option for obesity that could offer a differentiated profile, particularly for older patients at risk of muscle and bone loss.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Competitors (GLP-1 RA manufacturers): Potential for increased competition or partnership opportunities if enobosarm proves to be a valuable adjunct to existing GLP-1 RA therapies.

Next Steps

• Initiate Phase 2b PLATEAU clinical trial in Q1 calendar 2026.
• Anticipate interim analysis results for the PLATEAU trial in Q1 calendar year 2027.
• Continue clinical development of enobosarm for obesity, potentially exploring regulatory pathways based on incremental weight loss, preservation of physical function, or improvement in bone mineral density.
• Continue development of sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.

Key Dates

Recommendation

The significant reduction in net and operating losses, coupled with a substantial increase in cash, indicates improved financial health. More importantly, the positive Phase 2b QUALITY trial results for enobosarm and the clear regulatory pathways outlined by the FDA for its combination with GLP-1 RAs address a critical unmet need in obesity treatment (preserving lean mass and breaking weight loss plateaus). The planned initiation of the Phase 2b PLATEAU trial and the potential for bone mineral density as a primary endpoint further de-risk the development program and offer a strong competitive advantage against existing GLP-1 RAs. This progress suggests strong future growth potential for Veru.

Keywords

Veru Inc., VERU, biopharmaceutical, cardiometabolic diseases, inflammatory diseases, enobosarm, obesity, GLP-1 RA, semaglutide, PLATEAU clinical trial, QUALITY clinical trial, fat loss, lean mass preservation, physical function, bone mineral density, FDA regulatory pathway, Q1 FY2026 financial results, clinical stage, drug development, sabizabulin, atherosclerotic cardiovascular disease